Neurosigma Inc - Product Pipeline Analysis, 2019 Update

Published by Global Data on 12th November 2019 | Ref: 1463923 | This Product Is In Stock

$750 | Single User
$1500 | Site License
$2250 | Global License
$750 | Single User
$1500 | Site License
$2250 | Global License

Introduction

Summary

Neurosigma Inc (Neurosigma) is a life science company that develops and commercializes trigeminal nerve stimulation technologies for neurologic and psychiatric disorders. It offers Monarch eTNS System for treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD). The company offers treatments for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stress disorders. It also conducts preclinical research and development, and phase clinical trials. The company trigeminal nerve stimulation has been investigated as a therapy for epilepsy, depression, attention deficity hyperactivity disorder, and post-traumatic stress disorder, Lennox-Gastaut syndrome and traumatic brain injuries, among others. NeuroSigma is headquartered in Los Angeles, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Neurosigma Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Neurosigma Inc Company Overview

Neurosigma Inc Company Snapshot

Neurosigma Inc Pipeline Products and Ongoing Clinical Trials Overview

Neurosigma Inc – Pipeline Analysis Overview

Neurosigma Inc - Key Facts

Neurosigma Inc - Major Products and Services

Neurosigma Inc Pipeline Products by Development Stage

Neurosigma Inc Ongoing Clinical Trials by Trial Status

Neurosigma Inc Pipeline Products Overview

Deep Brain Stimulation System - Cachexia

Deep Brain Stimulation System - Cachexia Product Overview

Deep Brain Stimulation System - Obesity

Deep Brain Stimulation System - Obesity Product Overview

DELTA Stent

DELTA Stent Product Overview

Flow-Diverting TFN Stent

Flow-Diverting TFN Stent Product Overview

Micropatterned TFN Stent

Micropatterned TFN Stent Product Overview

Monarch eTNS System - Depression

Monarch eTNS System - Depression Product Overview

Monarch eTNS System - Depression Clinical Trial

Monarch eTNS System - Epilepsy

Monarch eTNS System - Epilepsy Product Overview

Monarch eTNS System - Epilepsy Clinical Trial

Monarch eTNS System - Lennox-Gastaut Syndrome

Monarch eTNS System - Lennox-Gastaut Syndrome Product Overview

Monarch eTNS System - Post-Traumatic Stress Disorder

Monarch eTNS System - Post-Traumatic Stress Disorder Product Overview

Monarch eTNS System - Traumatic Brain Injury

Monarch eTNS System - Traumatic Brain Injury Product Overview

sTNS System - Epilepsy

sTNS System - Epilepsy Product Overview

Thin Film Nitinol Flow Diverting Stent

Thin Film Nitinol Flow Diverting Stent Product Overview

Neurosigma Inc - Key Competitors

Neurosigma Inc - Key Employees

Neurosigma Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Neurosigma Inc, Recent Developments

Oct 08, 2019: NeuroSigma announces partnership with Quick Care Pharmacy for sales and distribution of the Monarch eTNS System in the US

Jun 27, 2019: NeuroSigma announces presentation of clinical trial data showing increased brain activity and improved cognition in children with ADHD Treated with eTNS

May 01, 2019: CCHR condemns FDA's approval of Electricity-Zapping for 'ADHD' kids

Apr 23, 2019: NeuroSigma announces FDA clearance of Monarch eTNS System as first non-drug treatment for pediatric ADHD

Apr 23, 2019: FDA clears NeuroSigma’s Monarch device to treat ADHD

Oct 30, 2017: UCLA Team Reports Positive Topline Results from Double-Blind Trial of NeuroSigma's Non-Invasive eTNS System for Treatment of Pediatric ADHD

Jan 28, 2016: Electric patch holds promise for treating PTSD

Dec 10, 2015: Preliminary Results Utilizing NeuroSigma's Monarch eTNS System for the Treatment of Traumatic Brain Injury Presented at the North American Neuromodulation Society Annual Meeting

Nov 16, 2015: NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD

May 04, 2015: NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

Additional Details

Publisher

Global Data

Publisher Information

Reference

1463923 | GDME328927PD

Number of Pages

42

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Data
06-12-2018

$750 USD

Published by Global Data
31-08-2017

$750 USD

This report is published by Global Data

Global Data deliver comprehensive, detailed market intelligence that provides a definitive picture of the markets they serve. Their data is complete, detailed, global and completely cross-country comparable.

With different types of data other providers don’t provide, our clients can access a variety of tools that add context to our core data including innovation tracking, sentiment analysis, price monitoring, M&A tracking, competitor intelligence, and city-level intelligence.

Download Free Report Summary PDF

Neurosigma Inc - Product Pipeline Analysis, 2019 Update | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.